[{"address1": "490 Arsenal Way", "address2": "Suite120", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 231 0700", "website": "https://www.c4therapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 110, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew J. Hirsch M.B.A.", "age": 53, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1081125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth C. Anderson M.D., Ph.D.", "age": 73, "title": "Co-Founder, Independent Director & Member of Scientific Advisory Board", "yearBorn": 1951, "fiscalYear": 2024, "totalPay": 45000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kendra  Adams", "title": "CFO & Treasurer", "fiscalYear": 2024, "totalPay": 711215, "exercisedValue": 0, "unexercisedValue": 50296}, {"maxAge": 1, "name": "Dr. Leonard M. J. Reyno M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 837480, "exercisedValue": 0, "unexercisedValue": 8625}, {"maxAge": 1, "name": "Dr. Nathanael S. Gray Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Mossler", "age": 50, "title": "Chief Accounting Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paige  Mahaney Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Solberg", "title": "Senior Manager of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jolie M. Siegel J.D.", "age": 48, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 610400, "exercisedValue": 1063000, "unexercisedValue": 1335958}, {"maxAge": 1, "name": "Ms. Kelly A. Schick", "age": 44, "title": "Chief People Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.45, "open": 2.4, "dayLow": 2.37, "dayHigh": 2.5, "regularMarketPreviousClose": 2.45, "regularMarketOpen": 2.4, "regularMarketDayLow": 2.37, "regularMarketDayHigh": 2.5, "payoutRatio": 0.0, "beta": 2.892, "forwardPE": -1.4444444, "volume": 754941, "regularMarketVolume": 754941, "averageVolume": 1994303, "averageVolume10days": 1744980, "averageDailyVolume10Day": 1744980, "bid": 2.44, "ask": 2.5, "bidSize": 3, "askSize": 20, "marketCap": 239378608, "fiftyTwoWeekLow": 1.085, "fiftyTwoWeekHigh": 5.1, "allTimeHigh": 51.21, "allTimeLow": 1.06, "priceToSalesTrailing12Months": 7.9506645, "fiftyDayAverage": 2.5046, "twoHundredDayAverage": 2.153125, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 108957616, "profitMargins": 0.0, "floatShares": 57859846, "sharesOutstanding": 96914418, "sharesShort": 4811669, "sharesShortPriorMonth": 3521151, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0496, "heldPercentInsiders": 0.07192, "heldPercentInstitutions": 0.75471, "shortRatio": 1.88, "shortPercentOfFloat": 0.0525, "impliedSharesOutstanding": 96914418, "bookValue": 2.082, "priceToBook": 1.1863593, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -119081000, "trailingEps": -1.67, "forwardEps": -1.71, "enterpriseToRevenue": 3.619, "enterpriseToEbitda": -0.931, "52WeekChange": -0.4166667, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 2.47, "targetHighPrice": 29.0, "targetLowPrice": 6.0, "targetMeanPrice": 11.85714, "targetMedianPrice": 10.0, "recommendationMean": 1.14286, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 191884000, "totalCashPerShare": 1.98, "ebitda": -117042000, "totalDebt": 61463000, "quickRatio": 5.52, "currentRatio": 5.755, "totalRevenue": 30108000, "debtToEquity": 39.806, "revenuePerShare": 0.423, "returnOnAssets": -0.23196, "returnOnEquity": -0.59981, "grossProfits": -81663000, "freeCashflow": -54987124, "operatingCashflow": -94481000, "revenueGrowth": -0.269, "grossMargins": -2.71234, "ebitdaMargins": 0.0, "operatingMargins": -2.10855, "financialCurrency": "USD", "symbol": "CCCC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.816326, "regularMarketPrice": 2.47, "marketState": "CLOSED", "shortName": "C4 Therapeutics, Inc.", "longName": "C4 Therapeutics, Inc.", "postMarketChangePercent": -0.8097158, "postMarketPrice": 2.45, "postMarketChange": -0.01999998, "regularMarketChange": 0.02, "regularMarketDayRange": "2.37 - 2.5", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1994303, "fiftyTwoWeekLowChange": 1.385, "fiftyTwoWeekLowChangePercent": 1.2764976, "fiftyTwoWeekRange": "1.085 - 5.1", "fiftyTwoWeekHighChange": -2.6299999, "fiftyTwoWeekHighChangePercent": -0.5156863, "fiftyTwoWeekChangePercent": -41.666668, "earningsTimestamp": 1762435800, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.67, "epsForward": -1.71, "epsCurrentYear": -1.52, "priceEpsCurrentYear": -1.625, "fiftyDayAverageChange": -0.03460002, "fiftyDayAverageChangePercent": -0.013814589, "twoHundredDayAverageChange": 0.31687498, "twoHundredDayAverageChangePercent": 0.1471698, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-02", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601645400000, "exchange": "NMS", "messageBoardId": "finmb_321572356", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1763164994, "regularMarketTime": 1763154001, "displayName": "C4 Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]